Sol-Gel Technologies (SLGL) Common Equity (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Common Equity of $22.8 million for Q4 2025, down 20.93% year-over-year from $28.8 million in Q4 2024, and down 20.93% on a QoQ basis from $28.8 million in Q4 2024.
Sol-Gel Technologies (SLGL) has 10 years of Common Equity data on file, last reported at $22.8 million in Q4 2025.
- Quarterly Common Equity fell 20.93% year-over-year to $22.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.8 million (down 20.93% YoY) and the FY2025 annual result came in at $22.8 million, down 20.93% from the prior year.
- Common Equity eased to $22.8 million in Q4 2025 per SLGL's latest filing, from $28.8 million in the prior quarter.
- Across five years, Common Equity topped out at $55.6 million in Q4 2021 and bottomed at $22.8 million in Q4 2025.
- The 5-year median for Common Equity is $38.6 million (2023), against an average of $37.6 million.
- The widest annual swing landed in 2021, when Common Equity rose 9.33%; it then decreased 25.34% in 2024.
- Tracing SLGL's Common Equity over 5 years: stood at $55.6 million in 2021, then dropped by 24.07% to $42.2 million in 2022, then declined by 8.45% to $38.6 million in 2023, then declined by 25.34% to $28.8 million in 2024, then fell by 20.93% to $22.8 million in 2025.
- Per Business Quant, the three latest SLGL Common Equity figures stand at $22.8 million (Q4 2025), $28.8 million (Q4 2024), and $38.6 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 22.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.81 Mn |
| Dec 31, 2024 | 28.85 Mn |
| Dec 31, 2023 | 38.64 Mn |
| Dec 31, 2022 | 42.21 Mn |
| Dec 31, 2021 | 55.59 Mn |
| Dec 31, 2020 | 50.85 Mn |
| Dec 31, 2019 | 52.47 Mn |
| Dec 31, 2018 | 63.91 Mn |
| Mar 31, 2018 | 87.04 Mn |
| Dec 31, 2017 | -52.70 Mn |
| Dec 31, 2016 | -31.34 Mn |